logo-loader
viewVolitionRx

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet.

Heading into 2020, Reynolds says the company's well placed to meet its key milestones - one of which is to advance its large-scale colorectal and lung cancer trials in Europe, Asia and the U.S.

Quick facts: VolitionRx

Price: 3.1 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $127.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx acquires epigenetic reagent company Octamer GmbH

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks through the rationale for its acquisition of epigenetic reagent company Octamer GmbH. Reynolds says they're paying around €650,000 euros ($725,000) in cash and stock and the deal is expected to close in January 2020. 

on 20/12/19

2 min read